ZA984700B - Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation. - Google Patents
Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation.Info
- Publication number
- ZA984700B ZA984700B ZA9804700A ZA984700A ZA984700B ZA 984700 B ZA984700 B ZA 984700B ZA 9804700 A ZA9804700 A ZA 9804700A ZA 984700 A ZA984700 A ZA 984700A ZA 984700 B ZA984700 B ZA 984700B
- Authority
- ZA
- South Africa
- Prior art keywords
- sub
- sup
- alkyl
- alkyloxy
- hydrogen
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 2
- IKMMPHALUZQNMN-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethyl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1CC1=CN=CN1 IKMMPHALUZQNMN-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 33
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 150000002431 hydrogen Chemical class 0.000 abstract 7
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- -1 amino, hydroxycarbonyl Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000004951 trihalomethoxy group Chemical group 0.000 abstract 1
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4737697P | 1997-06-02 | 1997-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA984700B true ZA984700B (en) | 1999-12-01 |
Family
ID=21948611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9804700A ZA984700B (en) | 1997-06-02 | 1998-06-01 | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation. |
Country Status (22)
Country | Link |
---|---|
US (4) | US6365600B1 (pt) |
EP (1) | EP0988038B1 (pt) |
JP (1) | JP4209472B2 (pt) |
KR (1) | KR100517832B1 (pt) |
CN (2) | CN1231215C (pt) |
AT (1) | ATE222104T1 (pt) |
AU (1) | AU740603B2 (pt) |
BR (1) | BR9810423A (pt) |
CA (1) | CA2290992C (pt) |
DE (1) | DE69807222T2 (pt) |
DK (1) | DK0988038T3 (pt) |
ES (1) | ES2182327T3 (pt) |
HK (2) | HK1025046A1 (pt) |
ID (1) | ID24675A (pt) |
IL (1) | IL133212A (pt) |
NO (1) | NO318834B1 (pt) |
NZ (1) | NZ501401A (pt) |
PT (1) | PT988038E (pt) |
RU (1) | RU2209066C2 (pt) |
TR (1) | TR199902923T2 (pt) |
WO (1) | WO1998055124A1 (pt) |
ZA (1) | ZA984700B (pt) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL133212A (en) | 1997-06-02 | 2005-12-18 | Janssen Pharmaceutica Nv | History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20020099438A1 (en) * | 1998-04-15 | 2002-07-25 | Furst Joseph G. | Irradiated stent coating |
PT1094815E (pt) | 1998-07-06 | 2004-04-30 | Janssen Pharmaceutica Nv | Inibidores da proteina farnesil transferase para tratamento de artropatias |
US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
CA2341739C (en) * | 1998-08-27 | 2005-07-12 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
KR100712226B1 (ko) * | 1998-12-23 | 2007-04-27 | 얀센 파마슈티카 엔.브이. | 1,2-어닐링된 퀴놀린 유도체 |
KR20010102073A (ko) | 1999-02-11 | 2001-11-15 | 실버스타인 아써 에이. | 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체 |
EP1106612B1 (en) * | 1999-11-30 | 2004-02-11 | Pfizer Products Inc. | Quinoline derivatives useful for inhibiting farnesyl protein transferase |
US6844357B2 (en) * | 2000-05-01 | 2005-01-18 | Pfizer Inc. | Substituted quinolin-2-one derivatives useful as antiproliferative agents |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
EP1317442B1 (en) | 2000-09-11 | 2005-11-16 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
FR2813791B1 (fr) * | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
AU2002220559A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
EP1322635B1 (en) | 2000-09-25 | 2006-03-22 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
US7173040B2 (en) | 2000-09-25 | 2007-02-06 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives |
US7067531B2 (en) | 2000-09-25 | 2006-06-27 | Angibaud Patrick Rene | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
US7153958B2 (en) | 2000-11-21 | 2006-12-26 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting benzoheterocyclic derivatives |
WO2002051835A1 (en) | 2000-12-27 | 2002-07-04 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
WO2003000266A1 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinolines and uses thereof |
ATE425978T1 (de) | 2001-12-19 | 2009-04-15 | Janssen Pharmaceutica Nv | Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
WO2003080058A1 (en) | 2002-03-22 | 2003-10-02 | Janssen Pharmaceutica. N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
JP4384505B2 (ja) | 2002-04-15 | 2009-12-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体 |
US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
US6638301B1 (en) * | 2002-10-02 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device with radiopacity |
US7838527B2 (en) | 2002-11-13 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Methods of treating cancer and related methods |
US20050154451A1 (en) * | 2003-12-18 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
ES2306082T3 (es) * | 2004-01-23 | 2008-11-01 | Janssen Pharmaceutica Nv | Quinolinas sustituidas y su utilizacion como inhibidores micobacterianos. |
US7211108B2 (en) * | 2004-01-23 | 2007-05-01 | Icon Medical Corp. | Vascular grafts with amphiphilic block copolymer coatings |
US7875624B2 (en) | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
EP1730113B1 (en) * | 2004-03-15 | 2016-12-28 | Genzyme Corporation | Process for the synthesis of a cxcr4 antagonist |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
CA2559221A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089502A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US7063720B2 (en) * | 2004-09-14 | 2006-06-20 | The Wallace Enterprises, Inc. | Covered stent with controlled therapeutic agent diffusion |
US20060083770A1 (en) * | 2004-10-15 | 2006-04-20 | Specialty Coating Systems, Inc. | Medical devices and methods of preparation and use |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
US8323333B2 (en) * | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
US7540995B2 (en) | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
US20060200048A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Removable sheath for device protection |
US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
WO2006110197A2 (en) | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
US20110178097A1 (en) | 2005-05-23 | 2011-07-21 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
KR101431279B1 (ko) | 2005-07-29 | 2014-08-20 | 리스버로직스 코퍼레이션 | 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달 |
WO2007075923A2 (en) | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
US20070148390A1 (en) * | 2005-12-27 | 2007-06-28 | Specialty Coating Systems, Inc. | Fluorinated coatings |
ATE547394T1 (de) | 2006-12-01 | 2012-03-15 | Bristol Myers Squibb Co | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen |
ES2454966T3 (es) | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
WO2008147788A1 (en) * | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
RU2520098C2 (ru) | 2008-06-26 | 2014-06-20 | Ресверлоджикс Корп. | Способы получения производных хиназолинона |
BRPI0920927A2 (pt) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
NZ595747A (en) | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
MX2014008856A (es) * | 2012-02-13 | 2014-12-15 | Hoffmann La Roche | Derivados de imidazolilcetona como inhibidores de aldosterona sintasa. |
EA026415B1 (ru) | 2012-10-16 | 2017-04-28 | Янссен Фармацевтика Нв | Связанные с метиленом хинолиниловые модуляторы ror-гамма-t |
US9309222B2 (en) * | 2012-10-16 | 2016-04-12 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
EP2909189B8 (en) * | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Heteroaryl linked quinolinyl modulators of ror-gamma-t |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
JP6423423B2 (ja) | 2013-10-15 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Rorγtのアルキル結合キノリニルモジュレーター |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
BR112016030273A2 (pt) | 2014-06-24 | 2017-08-22 | Icon Medical Corp | Dispositivo médico e método para formar o referido dispositivo |
CA2972771C (en) * | 2014-12-18 | 2024-06-11 | University Of South Carolina | Suppression of neointimal formation following vascular surgery using cdk8 inhibitors |
JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
DK3285768T3 (da) | 2015-04-21 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir |
ES2901506T3 (es) | 2015-08-17 | 2022-03-22 | Kura Oncology Inc | Métodos para tratar pacientes con cáncer con inhibidores de la farnesiltransferasa |
JP6864296B2 (ja) | 2015-12-14 | 2021-04-28 | エックス4 ファーマシューティカルズ, インコーポレイテッド | がんを処置する方法 |
EP3389652B1 (en) | 2015-12-14 | 2022-09-28 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
US11766506B2 (en) | 2016-03-04 | 2023-09-26 | Mirus Llc | Stent device for spinal fusion |
EP3440112A4 (en) | 2016-04-08 | 2019-10-09 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
PT3534885T (pt) | 2016-11-03 | 2021-04-13 | Kura Oncology Inc | Inibidores de farnesiltransferase para usar em métodos de tratamento do cancro |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN110204487B (zh) * | 2019-06-21 | 2021-09-28 | 江南大学 | 一种喹啉衍生物的合成方法 |
CN113072490B (zh) * | 2021-03-26 | 2022-08-16 | 中国海洋大学 | 一种替吡法尼喹啉酮中间体的高效合成方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE456347B (sv) | 1982-02-09 | 1988-09-26 | Ird Biomaterial Ab | Ytmodifierat fast substrat samt forfarande for framstellning derav |
US5213898A (en) | 1989-10-12 | 1993-05-25 | Norsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5049403A (en) | 1989-10-12 | 1991-09-17 | Horsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
JPH07112930A (ja) * | 1993-10-14 | 1995-05-02 | Kyowa Hakko Kogyo Co Ltd | 血管平滑筋細胞増殖抑制剤 |
JPH10506560A (ja) | 1995-04-19 | 1998-06-30 | シュナイダー(ユーエスエー)インク | 薬品を放出する被覆されたステント |
US5607475A (en) | 1995-08-22 | 1997-03-04 | Medtronic, Inc. | Biocompatible medical article and method |
US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
AU711142B2 (en) * | 1995-12-08 | 1999-10-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives |
IL133212A (en) | 1997-06-02 | 2005-12-18 | Janssen Pharmaceutica Nv | History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells |
-
1998
- 1998-05-25 IL IL13321298A patent/IL133212A/en not_active IP Right Cessation
- 1998-05-25 RU RU2000100032/14A patent/RU2209066C2/ru active
- 1998-05-25 JP JP50144099A patent/JP4209472B2/ja not_active Expired - Lifetime
- 1998-05-25 NZ NZ501401A patent/NZ501401A/en not_active IP Right Cessation
- 1998-05-25 DK DK98928332T patent/DK0988038T3/da active
- 1998-05-25 DE DE69807222T patent/DE69807222T2/de not_active Expired - Lifetime
- 1998-05-25 CN CNB98805700XA patent/CN1231215C/zh not_active Expired - Lifetime
- 1998-05-25 CN CNB2005101163581A patent/CN100525766C/zh not_active Expired - Lifetime
- 1998-05-25 AU AU80207/98A patent/AU740603B2/en not_active Expired
- 1998-05-25 EP EP98928332A patent/EP0988038B1/en not_active Expired - Lifetime
- 1998-05-25 ES ES98928332T patent/ES2182327T3/es not_active Expired - Lifetime
- 1998-05-25 WO PCT/EP1998/003182 patent/WO1998055124A1/en active IP Right Grant
- 1998-05-25 KR KR10-1999-7010744A patent/KR100517832B1/ko not_active IP Right Cessation
- 1998-05-25 CA CA002290992A patent/CA2290992C/en not_active Expired - Lifetime
- 1998-05-25 PT PT98928332T patent/PT988038E/pt unknown
- 1998-05-25 AT AT98928332T patent/ATE222104T1/de active
- 1998-05-25 BR BR9810423-3A patent/BR9810423A/pt not_active Application Discontinuation
- 1998-05-25 TR TR1999/02923T patent/TR199902923T2/xx unknown
- 1998-05-28 ID IDW991506A patent/ID24675A/id unknown
- 1998-06-01 ZA ZA9804700A patent/ZA984700B/xx unknown
-
1999
- 1999-05-25 US US09/445,009 patent/US6365600B1/en not_active Expired - Lifetime
- 1999-12-01 NO NO19995883A patent/NO318834B1/no not_active IP Right Cessation
-
2000
- 2000-07-08 HK HK00104198A patent/HK1025046A1/xx not_active IP Right Cessation
-
2001
- 2001-11-28 US US09/996,147 patent/US6743805B2/en not_active Expired - Lifetime
-
2003
- 2003-06-18 US US10/464,570 patent/US6734194B2/en not_active Expired - Lifetime
-
2004
- 2004-04-14 US US10/823,862 patent/US7253183B2/en not_active Expired - Lifetime
-
2006
- 2006-08-16 HK HK06109112.8A patent/HK1088820A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA984700B (en) | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation. | |
EP1162201A3 (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | |
RU2000100032A (ru) | Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы | |
PL356252A1 (en) | Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist | |
IL140930A0 (en) | Compounds and compositions for delivering active agents | |
NO931766L (no) | Topiske preparater for transdermal avlevering av forloeperlegemiddelderivater av morfin | |
FI955389A0 (fi) | Tandskyddande profylaktisk preparat och administreringsmedlen emot mellanoerpatogener | |
BG105534A (en) | 5ht1 means and method for the treatment of migraine | |
JP2003528808A5 (pt) | ||
UA50719C2 (uk) | Проліки для терапії пухлин і запальних захворювань | |
CA2430692A1 (en) | Geldanamycin derivative and use of same to treat cancer | |
HK1036970A1 (en) | Compounds and compositions for delivering active agents. | |
AU2274201A (en) | Compounds and compositions for delivering active agents | |
Diel | Bisphosphonates in the prevention of bone metastases: current evidence | |
NZ308391A (en) | Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers | |
PL1608349T3 (pl) | Układ do ustnego dostarczania zawierający środek przeciwbakteryjny i środek przeciwzapalny | |
MXPA02001571A (es) | Metodo de tratamiento para el cancer. | |
ITMI922331A1 (it) | Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
PL342614A1 (en) | Anticarcinogenic drugs | |
NO980419L (no) | Anvendelse av 1H,2,4-triazol derivater for å inhibere cancervekst | |
NZ511280A (en) | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists | |
Hattori et al. | Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth | |
AR026022A1 (es) | Metodo para el tratamiento de la obesidad | |
BR0012502A (pt) | Inibidores da expressão do gene para interleucina 5 | |
HUP9904578A2 (hu) | Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására |